drugset / Trial / NCT04510233

Ivermectin Nasal Spray for COVID19 Patients

NCT04510233

Phase 2 Unknown 60 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

The global escalation of COVID19 pandemic has put the health care system under pressure with urgent need for treatment. In the absence of vaccine and approved drug against SARS-COV2 over the past 6 months, the health authorities were obliged to re-purpose existing drugs to fight this pandemic.

Timeline

Start
2020-09
Primary completion
2020-10
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 1 ml Intranasal
Subject Ivermectin Small molecule 6 mg Intranasal

Indications